![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 21785-21788, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
The "integrin" terminology was applied in a
1987 review article (1) to describe a family of structurally,
immunochemically, and functionally related cell-surface heterodimeric
receptors, which integrated the extracellular matrix with
the intracellular cytoskeleton to mediate cell migration and adhesion.
The three original Repertoire Considerations--
A hallmark of the integrins is the
ability of individual family members to recognize multiple ligands.
Indeed, the extent of the integrin family pales in comparison with the
number of their ligands. Table I
summarizes the major extracellular ligands of integrins; the listing is
undoubtedly incomplete. The list includes a large number of
extracellular matrix proteins (bone matrix proteins, collagens,
fibronectins, fibrinogen, laminins, thrombospondins, vitronectin, and
von Willebrand factor), reflecting the primary function of integrins in
cell adhesion to extracellular matrices. Many "counter-receptors"
are ligands, reflecting the role of integrins in mediating cell-cell
interactions. Included are numerous microorganisms, which utilize
integrins to gain entry into cells. There are direct and multiple
linkages between integrins and host defense systems, created by their
recognition of hemostatic and complement factors. The preference of any
given integrin among its ligands is determined by relative affinity,
availability within a specific microenvironment, and the conformational
state of the ligand, which controls exposure of its integrin
recognition sequence.
Integrin Recognition Sequences--
A primary goal of many
structure-function analyses in the integrin field has been the
reduction of macromolecular ligands to minimal recognition sequences.
This endeavor has been highly successful, and many bioactive amino acid
sequences have been teased out of large extracellular matrix proteins
(5). The prototypic example is the RGD sequence. RGD was originally
identified as the sequence in fibronectin that engages the
fibronectin receptor, integrin Integrins as Metalloproteins--
Each integrin heterodimer
contains 3-5 divalent cation binding sites of relatively low affinity
(µM The Structural Basis of Divalent Ion Regulation--
There are at
least two structurally distinct classes of ion binding motifs within
integrins. A series of EF-hand-like domains are present in each of the
integrin
The second type of cation binding site in integrins is a metal
ion-dependent adhesion site (MIDAS) motif. The first
evidence for a unique cation binding motif came from mutagenesis
studies of the I domain of the
All integrin What Physiologic Role Do Ion Binding Sites Play in Regulating
Integrins?--
Despite the strong influence of divalent ions on cell
adhesion and ligand binding to integrins, information on the actual physiologic role of the ion binding sites is limited. One area where
there is clear physiologic relevance is the adhesion of bone-resorbing
osteoclasts. The osteoclast adheres to the bone surface primarily
through The The The crystal structures of several integrin and non-integrin I domains
have now been solved (e.g. Refs. 22-24). Each consists of
five parallel Although the I domains dominate the ligand binding functions of their
integrins, other regions of the The central role that platelet adhesive reactions play in
hemostasis has focused significant efforts on defining
Substantial data have accumulated regarding the location of potential
ligand contact sites within Two distinct, discontinuous regions within Studies of the ligand contacts in Several attempts have been made at developing a structural model of
integrin The data discussed above confirm that the ligand binding pocket
consists of portions of both the *
This minireview will be reprinted
in the 2000 Minireview Compendium, which
will be available in December, 2000. This is the first article of four in the
"Integrins Minireview Series."
§
To whom correspondence should be addressed: Joseph J. Jacobs Center
for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Mail
Code: NB50, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-8200;
Fax: 216-445-8204; E-mail: plowe@ccf.org.
Published, JBC Papers in Press, May 4, 2000, DOI 10.1074/jbc.R000003200
The abbreviations used are:
LC, ligand
competent;
MIDAS, metal ion-dependent adhesion site;
mAb, monoclonal antibody;
ICAM, intracellular adhesion molecule;
VCAM, vascular cell adhesion molecule;
MAdCAM, mucosal addressin cell
adhesion molecule.
MINIREVIEW
Ligand Binding to Integrins*
§,
,
, and
Joseph J. Jacobs Center for Thrombosis
and Vascular Biology, Cleveland Clinic Foundation, Cleveland, Ohio
44195, ¶ Vascular Biology Department, American Red Cross Holland
Laboratory, Rockville, Maryland 20855,
Del E. Webb Foundation
Research Laboratory, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, and ** Cancer Research Center, The Burnham Institute,
La Jolla, California 92037
![]()
INTRODUCTION
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
subunits (
1,
2,
and
3) identified have now expanded to eight, and the
number of
subunits stands at 17. These subunits interact
noncovalently in a restricted manner to form more than 20 family
members. The diversity of integrins is expanded further by alternative
splicing, post-translational modifications, and interactions with other
cell-surface and intracellular molecules (2-4). The number of
integrins and the remarkable breadth of their cellular distribution
support the statement that the phenotype of virtually every cell is
uniquely influenced by its display of integrins. Over the past 13 years, more than 14,000 scientific articles have dealt with various
aspects of integrin biology and almost 1,000 have appeared in the
Journal of Biological Chemistry. This article examines a
central aspect of integrin biology: ligand recognition and the
structural basis for this function.
![]()
Ligand Repertoire and Recognition
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
Integrin extracellular ligands
5
1,
but now is known to serve as a recognition motif in multiple ligands
for several different integrins (see Table II). Although RGD peptides
inhibit ligand binding to integrins with an RGD recognition
specificity (Table II), these
receptors can discriminate among RGD-containing ligands. The context of the RGD sequence (flanking residues, three-dimensional presentation, and individual features of the integrin binding pockets) determine whether productive interactions occur (6). As an illustrative example
of the nuances of the RGD recognition specificity, whereas both of the
3 integrins,
IIb
3 and
V
3, recognize fibrinogen, which contains
multiple RGD sequences, and RGD peptides inhibit the binding of
fibrinogen to these integrins, both integrins can recognize other
sequences in fibrinogen (7, 8). Thus, recognition of this seemingly
simple tripeptide sequence is complex. A second set of fibronectin
sequences also has received considerable attention: those recognized by
4
1. Originally, the CS-1 sequence, which resides in an alternatively spliced segment of fibronectin, was determined to be a recognition site, but now several additional fibronectin sequences have been identified that interact with
4
1 (9-11). Multiple recognition sites
also exist in fibrinogen for
M
2 (12). Two
generalizations can be derived from these examples: 1) integrin
recognition specificities can often be reduced to small peptide
sequences; and 2) peptide inhibition studies need to be complemented
with other approaches to assess the role of specific sequences in
ligand recognition by integrins.
Integrin recognition sequences
![]()
Divalent Cations and Ligand Binding to Integrins
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
1 to
mM
1), and the bound cations exert
profound effects on integrin function. Collectively, these bound
divalent ions can act as effectors, promoting ligand binding; as
antagonists, inhibiting ligand binding; and as selectors, changing the
ligand binding specificity. One proposal to explain the influential
role of cations on integrin function is that ligand and divalent cation
share a common binding pocket on the integrin. This hypothesis was
supported by data showing that RGD ligands could displace two
receptor-bound metal ions and that divalent ion and RGD peptide could
bind, in a mutually exclusive manner, a peptide from the
3 subunit (13). Thus, a "displacement model" was
proposed, in which RGD ligands initially form a ternary complex with
receptor-bound divalent ion; then, as contacts between RGD and integrin
stabilize, the divalent ion may be displaced. Recently, this model was
extended to other integrins (14); collagen displaced Tb3+
bound to the I domain of the
2 subunit. Dissection of
the ligand binding reaction into ligand association and dissociation
steps provided further insights into the roles of divalent ions in
integrin function (15). Using surface plasmon resonance, the
3 integrins were shown to contain two classes of ion
binding sites. One class must be occupied for ligand to bind,
ligand-competent (LC)1 sites;
and the second class has an inhibitory effect on ligand binding, I
sites. The I site(s) display specificity for Ca2+ and
increase the rate of ligand dissociation. Because the I sites are
allosteric to the ligand binding pocket, they can bind Ca2+
even when ligand is prebound to integrin, providing a potential mechanism for the release of pre-existing cell-matrix contacts. Thus,
it is the coordination between the LC and I cation binding sites that
regulates the ligand binding event.
subunits (16). The integrin EF-hand loops lack a glutamate
that is found at the 12th position in virtually all other EF-hand loops
and is one of the ligands for Ca2+. The absence of this
residue in integrins is likely to explain their lower affinity and
selectivity for divalent ions. Two studies have examined the ion and
ligand binding function of recombinant fragments containing the
integrin EF-hands. Gulino et al. (17) produced a fragment
composed of the four EF-hand sites within the
IIb
subunit and found that it contained two affinity classes for
Ca2+, which could also bind Mg2+ and
Mn2+ and fibrinogen, a physiologic ligand for this
integrin. These observations are generally consistent with results
obtained from Ca2+ binding studies on the purified integrin
(18) and synthetic peptides corresponding to the individual loops of
each EF-hand (19). The EF-hand domains of the
5 integrin
also contain two affinity classes of ion binding sites and can bind
fibronectin and RGD peptides (20). All four EF-hands were required for
ligand binding, even though each pair of EF-hands was able to bind
divalent ion.
M subunit (21). Soon
thereafter, the I domain of the
M subunit and other
integrin
subunits were crystallized (22-24). In Fig.
1, the crystal structures of two I
domains are displayed with the MIDAS motif at their upper surface. Within the MIDAS motif, five separate residues coordinate the divalent
ion. The first three are closely spaced within a
DXSXS motif; the fourth is a threonine separated
from the DXSXS in the primary structure by ~70
residues; and the fifth coordinating ligand is an aspartate about 100 residues downstream of the DXSXS. In the crystal
structure, two of the
MI domains were linked via a
Mg2+ ion in the MIDAS motif, and a glutamate from one I
domain donated a sixth coordinating ligand to the Mg2+
bound in an adjacent I domain. This quirk in the crystal structure provided evidence that metal ion bound to the MIDAS can ligand with
carboxylates donated from another protein, consistent with the cation
displacement model. Indeed, this finding has prompted the hypothesis
that such a structure is a snapshot of I domain bound with "ligand"
and led to the prevailing notion that integrins bind to their ligands
by "grabbing an Asp" (25).

View larger version (39K):
[in a new window]
Fig. 1.
Structures of representative I domains in
integrin
subunits. The ribbon diagrams
are derived from the crystal structures of the I domains of the
M subunit (left) and the
L
subunit (right). These I domains display the typical
helical/
strand fold of I domains. The cation bound in the MIDAS
motif appears on the upper face of the structures. These crystal
structures for the
M I domains were reported by Lee
et al. (22) and by Qu and Leahy (23) for the
L.
subunits may contain an ion binding site homologous to
a MIDAS motif. This proposition stems from early work showing that a
naturally occurring mutation of Y119D in integrin
IIb
3 led to a receptor with abnormal
ligand and cation binding functions (26), and it was proposed that this
residue was part of an EF-hand. In retrospect, this ion binding site is
more likely to be a MIDAS motif with Asp-119 being the first residue of
the DXSXS motif. Mutation of any of these
putative ion-coordinating residues within the
1,
2,
3, or
5 subunits
ablates ligand binding to integrins (e.g. Refs. 27 and 28).
Although the DXSXS motif appears to ligand with
metal, the residues that constitute the fourth and fifth coordinating
ligands in the
subunit MIDAS remain unclear and controversial
(27-29). The three-dimensional structure of a
subunit may be
necessary for resolution. Also, there is no structural information to
locate the I Ca2+ binding site that is found on most
integrins. All of the ion binding sites that have been located, the
EF-hand sites in the
subunits and the MIDAS motifs in the
subunits, appear to promote ion binding, i.e. are LC sites
(15, 27, 30). One of the more tantalizing hypotheses regarding the
location of this I site is that the ion binding site within the
integrin
subunits can fold into either an EF-hand or a MIDAS
domain. It may act as a MIDAS when Mn2+ or Mg2+
is present, but Ca2+ could induce an EF-hand conformation.
v
3 (31). Adhesion to the bone
surface must be tightly regulated to prevent excessive resorption.
Interestingly, as mineralized bone is resorbed, the concentration of
free Ca2+ beneath the osteoclast becomes elevated and
induces osteoclast detachment and cessation of resorption. This effect
may be mediated by the allosteric I Ca2+ binding site on
v
3. Another situation where the levels of
Ca2+ and Mg2+ fluctuate is in the fluid of
healing wounds (32). During the initial healing process, the levels of
Mg2+ increase, and the ratio of
Mg2+/Ca2+ elevates from the normal plasma ratio
of 0.4:1 to approach 1:1. Because Mg2+ generally promotes
cell adhesion and Ca2+ is generally inhibitory, this
increase in ratio may be "promigratory," facilitating wound
closure. Finally, the ion binding sites also may play a role in
integrin activation. Mn2+ increases the apparent
affinity/avidity of multiple integrins for their ligands.
Mn2+ binds to MIDAS motifs, and two conformations of the
MIDAS can be distinguished by the manner in which the bound metal is
coordinated (33, 34). Thus, Mn2+ could induce structural
rearrangements in the I domains, which result in activation. An equally
attractive hypothesis suggests that activation is regulated by the
binding of Ca2+ to the allosteric I site. Occupation of
this site by Ca2+ would maintain the integrin in a resting state.
![]()
The
2 Integrins, Representative I Domain-containing
Integrins
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
2 subfamily consists of four different integrin
receptors,
M
2 (CD11b/CD18, Mac-1, CR3,
Mo-1),
L
2 (CD11a/CD18, LFA-1),
X
2 (CD11c/CD18), and
D
2 (CD11d/CD18). These leukocyte
integrins are involved in virtually every aspect of leukocyte function, including the immune response, adhesion to and transmigration through
the endothelium, phagocytosis of pathogens, and leukocyte activation.
The importance of the
2 integrins is underscored by the
susceptibility of patients lacking these integrins to severe infections
(see Ref. 35, and references therein). However, excessive activation of
L
2 and
M
2
contributes to sustained inflammation, reperfusion injury, and tissue
damage. Recently, it has become possible to gauge the function of
individual
2 integrin receptors in mice rendered
selectively deficient in
M
2 and
L
2. The leukocyte integrins are the
subject of a separate review in this miniseries. The discussion herein
focuses primarily on their I domains and their role in ligand binding.
subunits of all
2 integrins contain an
inserted region of ~200 amino acids, termed the I or A
domain. Highly conserved I domains are found in several other integrin
subunits and other proteins, such as certain coagulation and
complement proteins. I domains mediate protein-protein interactions,
and in integrins, they are integrally involved in the binding of
protein ligands (14, 22, 36). I domains, including those in integrin
subunits, fold independently, can be expressed as recombinant
fragments, and can bind ligands. Even though I domains are highly
homologous to each other, they are highly selective for particular sets
of ligands. At the same time, a single I domain can recognize multiple and structurally unrelated ligands (see ligand repertoire of
M
2 in Table I). Thus, it is the
individual amino acid differences within the highly conserved
structural fold of the I domains that impart ligand specificity.
sheets surrounded by 5-6
helices, which are interconnected by flexible loops (see Fig. 1). The I domains of the
2 integrins contain the previously discussed cation
binding MIDAS motif. In the I domains of
M
2 and
L
2
shown, the binding interface for several ligands has been mapped to the
upper face, in close proximity to the bound cation (34, 37). Mutations in other faces of the I domains or outside the I domains can exert allosteric effects, either activating or inhibitory, on ligand binding
(34, 38, 39).
subunits do influence ligand
recognition. As examples, in
M
2 a mAb
(OKM1) recognizing an epitope outside the I domain but in the
M subunit inhibits ligand binding (40); and the EF-hand
regions in
L
2 and
2
1, integrins with I domains in their
subunits, contribute to ligand recognition (41, 42). The
M subunit, and perhaps other
subunits, contains a
lectin-like domain, which is involved in engagement of non-protein
ligands, and occupancy may modulate the function of the I domain (43).
The role of the
subunit in ligand binding to the leukocyte
integrins is complicated. Though the importance of the
subunit in
ligand recognition has been demonstrated using blocking mAbs and
site-directed mutagenesis (e.g. Ref. 44), its direct
involvement in ligand contact has yet to be established. Mutations in
the
2 subunit, which abolish ligand binding, may exert a
dominant-negative effect on ligand binding (45).
![]()
Ligand Binding to Integrins without I Domains: Paradigms from
IIb
3
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
IIb
3 recognition sequences within its
ligands and the ligand contact points within the receptor. Many of the
insights gained from these studies extrapolate to the
1
integrins because several of the
1 and both
3 integrins share a RGD recognition specificity. A
second recognition specificity of particular importance to the function
of
IIb
3 is the C terminus of the
fibrinogen
chain (46). Each sequence contains an aspartic acid that
is critical for recognition, perhaps through an interaction with
receptor-bound cation (26). The two recognition peptides inhibit the
binding of each other to
IIb
3 but may
bind to separate but allosterically linked sites (30, 47).
IIb
3. Mapping
the epitopes of inhibitory mAbs, enzymatic digestion of native
IIb
3, and the expression of soluble,
recombinant forms of
IIb
3 have indicated that the minimal ligand binding fragment contains the N-terminal half
of each subunit (48). The specificity of
IIb
3 versus
v
3 for ligands was mapped to the
N-terminal 334 residues of
IIb (49). Cross-linking
studies have demonstrated the existence of ligand contact points in the
N-terminal portions of
IIb (50) and
3
(51, 52), and it is likely that binding of macromolecular ligands to
IIb
3 involves multiple contacts in each
subunit. Essential residues identified to date can be grouped into two major regions: 1) the highly conserved segment, residues 95-400 of the
762 amino acids in
3; and 2) the seven N-terminal
repeats of
IIb.
3 clearly
contribute to the ligand binding function of the receptor. RGD peptides cross-link to a region of
3 defined by Asp-109 to
Glu-171 (52). An overlapping region of
3 (Glu-65 to
Glu-220) was identified by cross-linking of RGD peptides to
V
3 (53). As noted previously, a naturally
occurring point mutation in this region, D119Y, results in complete
loss of ligand binding function (26), as do mutations at residues in
this vicinity (54). The second potential ligand interactive site in
3 is defined by residues Ser-211 to Gly-222. Peptides
corresponding to this sequence and antibodies directed against these
peptides inhibit fibrinogen binding (55) as do natural mutations at
3 Arg-214 (56, 57). The importance of these two
discontinuous regions of
3 is likely because of their participation in the formation of a MIDAS motif (21, 22) although, as
noted above, it remains uncertain as to whether this region of
3 adopts an I domain fold (27, 29). Whereas the two
discontinuous segments of
3 are involved in cation
binding, they also may provide direct contact sites for ligand.
Peptides and recombinant fragments of
3 bind fibrinogen
and
-chain and RGD peptides (47, 58).
IIb have established a
role for its seven N-terminal repeats. As noted above, a recombinant fragment of
IIb containing the four EF-hand-like
sequences binds fibrinogen in a Ca2+- and
RGD-dependent manner (17). This region of
IIb has been further implicated in ligand binding
because ligand mimetic peptides cross-link within the second cation
binding repeat (50). Peptides from this region inhibit fibrinogen
binding to
IIb
3 and directly bind
fibrinogen in a Ca2+-dependent manner (59, 60).
Together, these data suggest a functional importance of the
IIb cation binding domains in ligand interactions.
Paradoxically, a minimized form of
IIb, Leu-1 to Gly-233, which does
not contain any of the divalent cation repeats, associated with
3 and recognized ligand (61).
subunits. A recent model proposes that the seven
N-terminal repeats adopt the fold of a
-propeller domain (62). These
domains contain seven four-stranded
-sheets, or "blades,"
arranged in a torus around a pseudosymmetry axis. Enzymes with known
-propeller folds have their active sites at the top of the
-propeller, typically where adjacent loops run in opposite directions. Consistent with this hypothesis, the
IIb
residues, Gly-184 to Gly-193, located in one loop, and
IIb Asp-224, located in a second loop, both predicted to
be at the top of the
-propeller, have been implicated in ligand
binding by site-directed mutagenesis (63, 64). The identification of
residues critical for ligand binding to
4
1 and
5
1
further supports the
-propeller model (65, 66). Nevertheless, this
model appears to contradict the data implicating the direct involvement
of the
IIb and
5 cation binding motifs in
ligand binding. The model places these motifs on the lower surface of
the propeller, spatially distant from the putative ligand contact
points on the upper surface of the propeller.
IIb and
3 subunits and is consistent with the concept that
binding of macromolecular ligands involves multiple contact points in
the receptor. An emerging model (Fig. 2)
is that
IIb
3 has at least two distinct
ligand binding domains that are intimately linked and allosterically controlled.
IIb
3 exhibits significant
conformational changes during activation and ligand binding. Therefore,
it will be important to understand how these changes influence the
individual ligand binding domains as well as how these changes affect
the manner in which the
IIb and
3
subunits fold against each other to establish a structural basis for
ligand binding to
IIb
3.

View larger version (21K):
[in a new window]
Fig. 2.
Top (upper) and side
(lower) views of a model of the ligand binding sites
on
IIb
3.
The numbers refer to the seven repeats in the
IIb subunit, and the Ca2+ shown is bound to
the MIDAS motif in the
3 subunit. In the low affinity
state, receptor conformation does not favor binding of macromolecular
ligands (L). Activation alters the spatial relationship of
the two subunits and the conformation of individual binding domains to
allow high affinity ligand interaction with multiple contact
sites.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
INTRODUCTION
Ligand Repertoire and...
Divalent Cations and Ligand...
The
2 Integrins,...
Ligand Binding to Integrins...
REFERENCES
1.
Hynes, R. O.
(1987)
Cell
48,
549-550
2.
Green, L. J.,
Mould, A. P.,
and Humphries, M. J.
(1998)
Int. J. Biochem. Cell Biol.
30,
179-184
3.
Porter, J. C.,
and Hogg, N.
(1998)
Trends Cell Biol.
8,
390-396
4.
De Melker, A. A.,
and Sonnenberg, A.
(1999)
Bioessays
21,
499-509
5.
Ruoslahti, E.
(1996)
Annu. Rev. Cell Biol.
12,
697-715
6.
Haas, T. A.,
and Plow, E. F.
(1994)
Curr. Opin. Cell Biol.
6,
656-662
7.
Yokoyama, K.,
Zhang, X.-P.,
Medved, L.,
and Takada, Y.
(1999)
Biochemistry
38,
5872-5877
8.
Farrell, D. H.,
Thiagarajan, P.,
Chung, D. W.,
and Davie, E. W.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10729-10732
9.
Wayner, E. A.,
Garcia-Pardo, A.,
Humphries, M. J.,
McDonald, J. A.,
and Carter, W. G.
(1989)
J. Cell Biol.
109,
1321-1330
10.
Mould, A. P.,
Komoriya, A.,
Yamada, K. M.,
and Humphries, M. J.
(1991)
J. Biol. Chem.
266,
3579-3585
11.
Domínguez-Jiménez, C.,
Sánchez-Aparicio, P.,
Albar, J. P.,
and García-Pardo, A.
(1996)
Cell Adhes. Commun.
4,
251-267
12.
Ugarova, T. P.,
Solovjov, D. A.,
Zhang, L.,
Loukinov, D. I.,
Yee, V. C.,
Medved, L. V.,
and Plow, E. F.
(1998)
J. Biol. Chem.
273,
22519-22527
13.
D'Souza, S. E.,
Haas, T. A.,
Piotrowicz, R. S.,
Byers-Ward, V.,
McGrath, D. E.,
Soule, H. R.,
Cierniewski, C. S.,
Plow, E. F.,
and Smith, J. W.
(1994)
Cell
79,
659-667
14.
Dickeson, S. K.,
Bhattacharyya-Pakrasei, M.,
Mathis, N. L.,
Schlesinger, P. H.,
and Santoro, S. A.
(1998)
Biochemistry
37,
11280-11288
15.
Hu, D. D.,
Barbas, C. F., III,
and Smith, J. W.
(1996)
J. Biol. Chem.
271,
21745-21751
16.
Tuckwell, D. S.,
Brass, A.,
and Humphries, M. J.
(1992)
Biochem. J.
285,
325-331
17.
Gulino, D.,
Boudignon, C.,
Zhang, L. Y.,
Concord, E.,
Rabiet, M. J.,
and Marguerie, G.
(1992)
J. Biol. Chem.
267,
1001-1007
18.
Rivas, G. A.,
and Gonzalez-Rodriguez, J.
(1991)
Biochem. J.
276,
35-40
19.
Cierniewski, C. S.,
Haas, T. A.,
Smith, J. W.,
and Plow, E. F.
(1994)
Biochemistry
33,
12238-12246
20.
Baneres, J. L.,
Roquet, F.,
Green, M.,
LeCalvez, H.,
and Parello, J.
(1998)
J. Biol. Chem.
273,
24744-24753
21.
Michishita, M.,
Videm, V.,
and Arnaout, M. A.
(1993)
Cell
72,
857-867
22.
Lee, J.-O.,
Rieu, P.,
Arnaout, M. A.,
and Liddington, R.
(1995)
Cell
80,
631-638
23.
Qu, A.,
and Leahy, D. J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10277-10281
24.
Emsley, J.,
King, S. L.,
Bergelson, J. M.,
and Liddington, R. C.
(1997)
J. Biol. Chem.
272,
28512-28517
25.
Bergelson, J. M.,
and Hemler, M. E.
(1995)
Curr. Biol.
5,
615-617
26.
Loftus, J. C.,
O'Toole, T. E.,
Plow, E. F.,
Glass, A.,
Frelinger, A. L.,
and Ginsberg, M. H.
(1990)
Science
249,
915-918
27.
Lin, C. K. E.,
Ratnikov, B. I.,
Tsai, P. M.,
Gonzalez, E. R.,
McDonald, S.,
Pelletier, A. J.,
and Smith, J. W.
(1997)
J. Biol. Chem.
272,
14236-14243
28.
Puzon-McLaughlin, W.,
and Takada, Y.
(1996)
J. Biol. Chem.
271,
20438-20443
29.
Tozer, E. C.,
Liddington, R. C.,
Sutcliffe, M. J.,
Smeeton, A. H.,
and Loftus, J. C.
(1996)
J. Biol. Chem.
271,
21978-21984
30.
Hu, D. D.,
White, C. A.,
Panzer-Knodle, S.,
Page, J. D.,
Nicholson, N.,
and Smith, J. W.
(1999)
J. Biol. Chem.
274,
4633-4639
31.
Ross, F. P.,
Chappel, J.,
Alvarez, J. I.,
Sander, D.,
Butler, W. T.,
Farach-Carson, M. C.,
Mintz, K. A.,
Robey, P. G.,
Teitelbaum, S. L.,
and Cheresh, D. A.
(1993)
J. Biol. Chem.
268,
9901-9907
32.
Grzesiak, J. J.,
and Pierschbacher, M. D.
(1995)
J. Clin. Invest.
95,
227-233
33.
Lee, J.-O.,
Bankston, L. A.,
Arnaout, M. A.,
and Liddington, R. C.
(1995)
Structure
3,
1333-1340
34.
Li, R.,
Rieu, P.,
Griffith, D. L.,
Scott, D.,
and Arnaout, M. A.
(1998)
J. Cell Biol.
143,
1523-1534
35.
Harris, E. S.,
McIntyre, T. M.,
Prescott, S. M.,
and Zimmerman, G. A.
(2000)
J. Biol. Chem.
275,
23409-23412
36.
Randi, A. M.,
and Hogg, N.
(1994)
J. Biol. Chem.
269,
12395-12398
37.
Zhang, L.,
and Plow, E. F.
(1997)
J. Biol. Chem.
272,
17558-17564
38.
Zhang, L.,
and Plow, E. F.
(1996)
J. Biol. Chem.
271,
29953-29957
39.
Oxvig, C.,
Lu, C.,
and Springer, T. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2215-2220
40.
Thornton, B. P.,
Vetvicka, V.,
Pitman, M.,
Goldman, R. C.,
and Ross, G. D.
(1996)
J. Immunol.
156,
1235-1246
41.
Stanley, P.,
Bates, P. A.,
Harvey, J.,
Bennett, R. I.,
and Hogg, N.
(1994)
EMBO J.
13,
1790-1798
42.
Dickeson, S. K.,
Walsh, J. J.,
and Santoro, S. A.
(1997)
J. Biol. Chem.
272,
7661-7668
43.
Vetvicka, V.,
Thornton, B. P.,
and Ross, G. D.
(1996)
J. Clin. Invest.
98,
50-61
44.
Bajt, M. L.,
Goodman, T.,
and McGuire, S. L.
(1995)
J. Biol. Chem.
270,
94-98
45.
Forsyth, C. B.,
Plow, E. F.,
and Zhang, L.
(1998)
J. Immunol.
161,
6198-6205
46.
Kloczewiak, M.,
Timmons, S.,
and Hawiger, J.
(1982)
Biochem. Biophys. Res. Commun.
107,
181-187
47.
Cierniewski, C. S.,
Byzova, T.,
Papierak, M.,
Haas, T. A.,
Niewiarowska, J.,
Zhang, L.,
Cieslak, M.,
and Plow, E. F.
(1999)
J. Biol. Chem.
274,
16923-16932
48.
Loftus, J. C.,
Smith, J. W.,
and Ginsberg, M. H.
(1994)
J. Biol. Chem.
269,
25235-25238
49.
Loftus, J. C.,
Halloran, C. E.,
Ginsberg, M. H.,
Feigen, L. P.,
Zablocki, J. A.,
and Smith, J. W.
(1996)
J. Biol. Chem.
271,
2033-2039
50.
D'Souza, S. E.,
Ginsberg, M. H.,
Burke, T. A.,
and Plow, E. F.
(1990)
J. Biol. Chem.
265,
3440-3446
51.
Santoro, S. A.,
and Lawing, W. J., Jr.
(1987)
Cell
48,
867-873
52.
D'Souza, S. E.,
Ginsberg, M. H.,
Lam, S. C. T.,
and Plow, E. F.
(1988)
J. Biol. Chem.
263,
3943-3951
53.
Smith, J. W.,
and Cheresh, D. A.
(1988)
J. Biol. Chem.
263,
18726-18731
54.
Basani, R. B.,
Brown, D. L.,
Vilaire, G.,
Bennett, J. S.,
and Poncz, M.
(1997)
Blood
90,
3082-3088
55.
Charo, I. F.,
Nannizzi, L.,
Phillips, D. R.,
Hsu, M. A.,
and Scarborough, R. M.
(1991)
J. Biol. Chem.
266,
1415-1421
56.
Bajt, M. L.,
Ginsberg, M. H.,
Frelinger, A. L., III,
Berndt, M. C.,
and Loftus, J. C.
(1992)
J. Biol. Chem.
267,
3789-3794
57.
Lanza, F.,
Stierlé, A.,
Fournier, D.,
Morales, M.,
André, G.,
Nurden, A. T.,
and Cazenave, J.-P.
(1992)
J. Clin. Invest.
89,
1995-2004
58.
Alemany, M.,
Concord, E.,
Garin, J.,
Vinçon, M.,
Giles, A.,
Marguerie, G.,
and Gulino, D.
(1996)
Blood
87,
592-601
59.
D'Souza, S. E.,
Ginsberg, M. H.,
Matsueda, G. R.,
and Plow, E. F.
(1991)
Nature
350,
66-68
60.
Taylor, D. B.,
and Gartner, T. K.
(1992)
J. Biol. Chem.
267,
11729-11733
61.
McKay, B. S.,
Annis, D. S.,
Honda, S.,
Christie, D.,
and Kunicki, T. J.
(1996)
J. Biol. Chem.
271,
30544-30547
62.
Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
65-72
63.
Kamata, T.,
Irie, A.,
Tokuhira, M.,
and Takada, Y.
(1996)
J. Biol. Chem.
271,
18610-18615
64.
Tozer, E. C.,
Baker, E. K.,
Ginsberg, M. H.,
and Loftus, J. C.
(1999)
Blood
93,
918-924
65.
Kamata, T.,
Puzon, W.,
and Takada, Y.
(1995)
Biochem. J.
305,
945-951
66.
Mould, A. P.,
Burrows, L.,
and Humphries, M. J.
(1998)
J. Biol. Chem.
273,
25664-25667
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. V. Veettil, S. Sadagopan, N. Sharma-Walia, F.-Z. Wang, H. Raghu, L. Varga, and B. Chandran Kaposi's Sarcoma-Associated Herpesvirus Forms a Multimolecular Complex of Integrins ({alpha}V{beta}5, {alpha}V{beta}3, and {alpha}3{beta}1) and CD98-xCT during Infection of Human Dermal Microvascular Endothelial Cells, and CD98-xCT Is Essential for the Postentry Stage of Infection J. Virol., December 15, 2008; 82(24): 12126 - 12144. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Weinlander, E. Naschberger, M. H. Lehmann, P. Tripal, W. Paster, H. Stockinger, C. Hohenadl, and M. Sturzl Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin {alpha}4 expression FASEB J, December 1, 2008; 22(12): 4168 - 4178. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Chudakova, Y. H. Zeidan, B. W. Wheeler, J. Yu, S. A. Novgorodov, M. S. Kindy, Y. A. Hannun, and T. I. Gudz Integrin-associated Lyn Kinase Promotes Cell Survival by Suppressing Acid Sphingomyelinase Activity J. Biol. Chem., October 24, 2008; 283(43): 28806 - 28816. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Q. Ma, J. Qin, C. Wu, and E. F. Plow Kindlin-2 (Mig-2): a co-activator of {beta}3 integrins J. Cell Biol., October 14, 2008; 181(3): 439 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-L. Tang, A. Vararattanavech, and S.-M. Tan Urokinase-type Plasminogen Activator Receptor Induces Conformational Changes in the Integrin {alpha}M{beta}2 Headpiece and Reorientation of Its Transmembrane Domains J. Biol. Chem., September 12, 2008; 283(37): 25392 - 25403. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gaudreault, F. Vigneault, M.-E. Gingras, S. Leclerc, P. Carrier, L. Germain, and S. L. Guerin Transcriptional Regulation of the Human {alpha}6 Integrin Gene by the Transcription Factor NFI during Corneal Wound Healing Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3758 - 3767. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Miltyk, A. Surazynski, J. Grabowska, and J. A. Palka Prolidase Dependent Inhibition of Collagen Biosynthesis in Chinese Hamster Ovary Cells J. Biochem., September 1, 2008; 144(3): 409 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Schroeter, M. Leifheit, P. Sudholt, N.-M. Heida, C. Dellas, I. Rohm, F. Alves, M. Zientkowska, S. Rafail, M. Puls, et al. Leptin Enhances the Recruitment of Endothelial Progenitor Cells Into Neointimal Lesions After Vascular Injury by Promoting Integrin-Mediated Adhesion Circ. Res., August 29, 2008; 103(5): 536 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Petropolis, J. C. Fernandes Rodrigues, B. da Rocha-Azevedo, and F. C. e Silva-Filho The binding of Tritrichomonas foetus to immobilized laminin-1 and its role in the cytotoxicity exerted by the parasite Microbiology, August 1, 2008; 154(8): 2283 - 2290. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, X.-T. Bai, K.-Y. Zhu, Y. Jin, M. Deng, H.-Y. Le, Y.-F. Fu, Y. Chen, J. Zhu, A. T. Look, et al. In Vivo Interstitial Migration of Primitive Macrophages Mediated by JNK-Matrix Metalloproteinase 13 Signaling in Response to Acute Injury J. Immunol., August 1, 2008; 181(3): 2155 - 2164. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Shi and J. Sottile Caveolin-1-dependent {beta}1 integrin endocytosis is a critical regulator of fibronectin turnover J. Cell Sci., July 15, 2008; 121(14): 2360 - 2371. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Spitaleri, S. Mari, F. Curnis, C. Traversari, R. Longhi, C. Bordignon, A. Corti, G.-P. Rizzardi, and G. Musco Structural Basis for the Interaction of isoDGR with the RGD-binding Site of {alpha}v{beta}3 Integrin J. Biol. Chem., July 11, 2008; 283(28): 19757 - 19768. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Chavakis, G. Carmona, C. Urbich, S. Gottig, R. Henschler, J. M. Penninger, A. M. Zeiher, T. Chavakis, and S. Dimmeler Phosphatidylinositol-3-Kinase-{gamma} Is Integral to Homing Functions of Progenitor Cells Circ. Res., April 25, 2008; 102(8): 942 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Tsai, C.-W. Chang, Y.-S. Lin, W.-J. Chuang, J.-J. Wu, C.-C. Liu, P.-J. Tsai, and M. T. Lin Streptococcal Pyrogenic Exotoxin B-Induced Apoptosis in A549 Cells Is Mediated through {alpha}v{beta}3 Integrin and Fas Infect. Immun., April 1, 2008; 76(4): 1349 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Carmona, E. Chavakis, U. Koehl, A. M. Zeiher, and S. Dimmeler Activation of Epac stimulates integrin-dependent homing of progenitor cells Blood, March 1, 2008; 111(5): 2640 - 2646. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-Q. Wang, H. Li, T. Oliver, M. Glogauer, J. Guo, and Y.-W. He Integrin {beta}1 Regulates Phagosome Maturation in Macrophages through Rac Expression J. Immunol., February 15, 2008; 180(4): 2419 - 2428. [Abstract] [Full Text] [PDF] |